lapatinib has been researched along with gallic acid in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (gallic acid) | Trials (gallic acid) | Recent Studies (post-2010) (gallic acid) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 4,793 | 42 | 2,579 |
| Protein | Taxonomy | lapatinib (IC50) | gallic acid (IC50) |
|---|---|---|---|
| Urokinase-type plasminogen activator | Homo sapiens (human) | 6.6 | |
| Tissue-type plasminogen activator | Homo sapiens (human) | 6.6 | |
| Plasminogen activator inhibitor 1 | Homo sapiens (human) | 6.6 | |
| Urokinase-type plasminogen activator | Mus musculus (house mouse) | 6.6 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 4.03 | |
| Matrilysin | Homo sapiens (human) | 4.03 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 4.65 | |
| Alpha-synuclein | Homo sapiens (human) | 4.43 | |
| 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 | Homo sapiens (human) | 4.03 | |
| Polypeptide N-acetylgalactosaminyltransferase 2 | Homo sapiens (human) | 1.37 | |
| Alpha-(1,3)-fucosyltransferase 7 | Homo sapiens (human) | 4.03 | |
| CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 | Homo sapiens (human) | 4.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blancafort, A; Brugada, R; Campuzano, Ò; Carrión-Salip, D; Giró-Perafita, A; Gómez-Miragaya, J; González-Suárez, E; Massaguer, A; Oliveras, G; Palafox, M; Palomeras, S; Puig, T; Turrado, C | 1 |
1 other study(ies) available for lapatinib and gallic acid
| Article | Year |
|---|---|
Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Catechin; Cell Adhesion; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatty Acid Synthase, Type I; Female; Gallic Acid; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Naphthalenes; Neoplasm Invasiveness; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Sirolimus; Trastuzumab | 2015 |